id
stringlengths
9
11
source
stringclasses
1 value
title
stringlengths
15
560
text
stringlengths
2k
153k
PMC4281461
core_pubmed_pmc
Pharmacokinetic Comparative Study of Gastrodin and Rhynchophylline after Oral Administration of Different Prescriptions of Yizhi Tablets in Rats by an HPLC-ESI/MS Method
Pharmacokinetic Comparative Study of Gastrodin and Rhynchophylline after Oral Administration of Different Prescriptions of Yizhi Tablets in Rats by an HPLC-ESI/MS Method Abstract Pharmacokinetic characters of rhynchophylline (RIN), gastrodin (GAS), and gastrodigenin ( p -hydroxybenzyl alcohol, HBA) were investigated af...
PMC9669616
core_pubmed_pmc
The recommended dosage regimen for caspofungin in patients with higher body weight or hypoalbuminaemia will result in low exposure: Five years of data based on a population pharmacokinetic model and Monte-Carlo simulations
The recommended dosage regimen for caspofungin in patients with higher body weight or hypoalbuminaemia will result in low exposure: Five years of data based on a population pharmacokinetic model and Monte-Carlo simulations Abstract Background: To develop a population pharmacokinetic (PPK) model for caspofungin, identif...
PMC11326355
core_pubmed_pmc
Phase I study on the pharmacokinetics of intravaginal, self-administered artesunate vaginal pessaries among women in Kenya
Phase I study on the pharmacokinetics of intravaginal, self-administered artesunate vaginal pessaries among women in Kenya Abstract Abstract Cervical cancer remains a significant global health issue, especially in low- and middle-income countries (LMICs), where access to prevention and treatment is limited and women ar...
PMC11496126
core_pubmed_pmc
Formulation development, characterization, and evaluation of sorafenib-loaded PLGA–chitosan nanoparticles
Formulation development, characterization, and evaluation of sorafenib-loaded PLGA–chitosan nanoparticles Abstract Abstract The basic purpose of this work was to develop environmentally friendly, biodegradable, and biocompatible polymeric nanoparticles of sorafenib that can effectively release the desired drug in a cus...
PMC11091963
core_pubmed_pmc
Development and Preclinical Evaluation of a Copper-64-Labeled Antibody Targeting Glycine-Alanine Dipeptides for PET Imaging of C9orf72-Associated Amyotrophic Lateral Sclerosis/Frontotemporal Dementia
Development and Preclinical Evaluation of a Copper-64-Labeled Antibody Targeting Glycine-Alanine Dipeptides for PET Imaging of C9orf72-Associated Amyotrophic Lateral Sclerosis/Frontotemporal Dementia Abstract Abstract Aggregating poly(glycine-alanine) (poly-GA) is derived from the unconventional translation of the path...
PMC10941605
core_pubmed_pmc
Development and application of neonatal physiology‐based pharmacokinetic models of amikacin and fosfomycin to assess pharmacodynamic target attainment
Development and application of neonatal physiology‐based pharmacokinetic models of amikacin and fosfomycin to assess pharmacodynamic target attainment Abstract Abstract Antimicrobial resistance increasingly complicates neonatal sepsis in a global context. Fosfomycin and amikacin are two agents being tested in an ongoin...
PMC12198660
core_pubmed_pmc
Qishiwei Zhenzhu Pills Protect Against Cerebral Ischemia via the P53/Cytochrome C/Apoptotic Protease Activating Factor 1‐Mediated Mitochondrial Apoptosis Pathway
Qishiwei Zhenzhu Pills Protect Against Cerebral Ischemia via the P53/Cytochrome C/Apoptotic Protease Activating Factor 1‐Mediated Mitochondrial Apoptosis Pathway Abstract ABSTRACT Background Qishiwei Zhenzhu pills (QSWZZP, Tibetan name: ) originated from Ershiwuwei Zhenzhu mother pills in the eighth century AD and are ...
PMC5225172
core_pubmed_pmc
A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors
A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors Abstract Purpose To evaluate the safety, tolerability, pharmacokinetics, and efficacy of the intravenously administered pan-PI3K inhibitor copanlisib in Japanese patients with advanced or refractory so...
PMC8247050
core_pubmed_pmc
Pharmacokinetics and Safety of the Selective Progesterone Receptor Modulator Vilaprisan in Chinese Healthy Postmenopausal Women
Pharmacokinetics and Safety of the Selective Progesterone Receptor Modulator Vilaprisan in Chinese Healthy Postmenopausal Women Abstract Abstract Vilaprisan is a novel selective progesterone receptor modulator for the long‐term treatment of uterine fibroids and endometriosis. This study investigated the pharmacokinetic...
PMC7407002
core_pubmed_pmc
In Silico Head-to-Head Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL in Type 1 Diabetes
In Silico Head-to-Head Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL in Type 1 Diabetes Abstract Abstract Background: Second-generation long-acting insulin glargine 300 U/mL (Gla-300) and degludec 100 U/mL (Deg-100) provide novel basal insulin therapies for the treatment of type 1 diabetes (T1D)...
PMC4728293
core_pubmed_pmc
Weight‐HbA1c‐insulin‐glucose model for describing disease progression of type 2 diabetes
Weight‐HbA1c‐insulin‐glucose model for describing disease progression of type 2 diabetes Abstract Abstract A previous semi‐mechanistic model described changes in fasting serum insulin (FSI), fasting plasma glucose (FPG), and glycated hemoglobin (HbA1c) in patients with type 2 diabetic mellitus (T2DM) by modeling insuli...
PMC11601169
core_pubmed_pmc
Deconvoluting zavegepant drug–drug interactions: A phase I study to evaluate the effects of rifampin and itraconazole on zavegepant pharmacokinetics
Deconvoluting zavegepant drug–drug interactions: A phase I study to evaluate the effects of rifampin and itraconazole on zavegepant pharmacokinetics Abstract Abstract Zavegepant is a calcitonin gene‐related peptide receptor antagonist for acute migraine treatment. This Phase I, open‐label, fixed‐sequence study evaluate...
PMC7550283
core_pubmed_pmc
The Predictive Value of Glomerular Filtration Rate-Based Scaling of Pediatric Clearance and Doses for Drugs Eliminated by Glomerular Filtration with Varying Protein-Binding Properties
The Predictive Value of Glomerular Filtration Rate-Based Scaling of Pediatric Clearance and Doses for Drugs Eliminated by Glomerular Filtration with Varying Protein-Binding Properties Abstract Abstract Introduction For drugs eliminated by glomerular filtration (GF), clearance (CL) is determined by GF rate (GFR) and the...
PMC12166193
core_pubmed_pmc
A Randomized, Double‐Blind, 2‐Treatment, 2‐Period, Crossover Phase 1 Study to Compare the Pharmacokinetics, Safety and Tolerability of 60 IU /Kg of Abcertin and Cerezyme in Healthy Volunteers Following a Single Intravenous Administration
A Randomized, Double‐Blind, 2‐Treatment, 2‐Period, Crossover Phase 1 Study to Compare the Pharmacokinetics, Safety and Tolerability of 60 IU /Kg of Abcertin and Cerezyme in Healthy Volunteers Following a Single Intravenous Administration Abstract ABSTRACT Background Imiglucerase (Cerezyme; Sanofi, Paris, France), an an...
PMC8970883
core_pubmed_pmc
Simultaneous Determination of Seven Phenolic Acids, Two Flavonoids, and Tussilagone in Rat Plasma after Administration of Farfarae Flos Extract by LC–MS/MS
Simultaneous Determination of Seven Phenolic Acids, Two Flavonoids, and Tussilagone in Rat Plasma after Administration of Farfarae Flos Extract by LC–MS/MS Abstract Abstract A simple LC-MS/MS method was established for the simultaneous quantitative analysis of concentration of seven phenolic acids, two flavonoids, and ...
PMC3680019
core_pubmed_pmc
Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study
Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study Abstract Abstract Background HIV infection, anti-tuberculosis and efavirenz therapy are associated with neuropsychological effects. We ev...
PMC5153275
core_pubmed_pmc
Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations
Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations Abstract The majority of invasive mold infections diagnosed in immunocompromised cancer patients include invasive aspergillosis (IA) and mucormycosis. Despite timely and effective...
PMC11726090
core_pubmed_pmc
Nonneutralizing antibodies in Nordic persons with moderate hemophilia A and B (the MoHem study)
Nonneutralizing antibodies in Nordic persons with moderate hemophilia A and B (the MoHem study) Abstract Abstract Background The impact of nonneutralizing antibodies (NNAs) in moderate hemophilia is elusive. Objectives To explore the presence of NNAs in Nordic persons with moderate hemophilia A (MHA) and B (MHB) in rel...
PMC8724172
core_pubmed_pmc
The effect of potent CYP2D6 inhibition on the pharmacokinetics and safety of deutetrabenazine in healthy volunteers
The effect of potent CYP2D6 inhibition on the pharmacokinetics and safety of deutetrabenazine in healthy volunteers Abstract Purpose Deutetrabenazine is a deuterated form of tetrabenazine with a confirmed lower rate of CYP2D6 metabolism of the active metabolites, α- and β-HTBZ. In this study, we assessed the effect of ...
PMC7341468
core_pubmed_pmc
Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days
Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days Abstract Background A trough concentration (C min ) ≥20 μg/mL of teicoplanin is recommended for the treatment of serious methicillin-resis...
PMC10083989
core_pubmed_pmc
Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH)
Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH) Abstract Nonalcoholic fatty liver disease (NAFLD), representing a clinical spectrum ranging from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH), is rapi...
PMC6770728
core_pubmed_pmc
CYP2D6 Genotype Predicts Plasma Concentrations of Tamoxifen Metabolites in Ethiopian Breast Cancer Patients
CYP2D6 Genotype Predicts Plasma Concentrations of Tamoxifen Metabolites in Ethiopian Breast Cancer Patients Abstract Tamoxifen displays wide inter-individual variability (IIV) in its pharmacokinetics and treatment outcome. Data on tamoxifen pharmacokinetics and pharmacogenetics from black African breast cancer patient ...
PMC6357488
core_pubmed_pmc
Effects of bupivacaine or levobupivacaine on cerebral oxygenation during spinal anesthesia in elderly patients undergoing orthopedic surgery for hip fracture: a randomized controlled trial
Effects of bupivacaine or levobupivacaine on cerebral oxygenation during spinal anesthesia in elderly patients undergoing orthopedic surgery for hip fracture: a randomized controlled trial Abstract Background Bupivacaine and levobupivacaine have similar pharmacokinetic and pharmacodynamic characteristics, and are used ...
PMC10745386
core_pubmed_pmc
The Bioavailability of Drugs—The Current State of Knowledge
The Bioavailability of Drugs—The Current State of Knowledge Abstract Drug bioavailability is a crucial aspect of pharmacology, affecting the effectiveness of drug therapy. Understanding how drugs are absorbed, distributed, metabolized, and eliminated in patients’ bodies is essential to ensure proper and safe treatment....
PMC9958674
core_pubmed_pmc
Pharmacodynamic and Pharmacokinetic Drug Interactions between Fexuprazan, a Novel Potassium-Competitive Inhibitor, and Aspirin, in Healthy Subjects
Pharmacodynamic and Pharmacokinetic Drug Interactions between Fexuprazan, a Novel Potassium-Competitive Inhibitor, and Aspirin, in Healthy Subjects Abstract Acid-reducing agents are commonly used for the prevention of aspirin-induced gastrointestinal complications such as peptic ulcers. As a novel potassium-competitive...
PMC8839615
core_pubmed_pmc
The Biological Fate of Pharmaceutical Excipient β-Cyclodextrin: Pharmacokinetics, Tissue Distribution, Excretion, and Metabolism of β-Cyclodextrin in Rats
The Biological Fate of Pharmaceutical Excipient β-Cyclodextrin: Pharmacokinetics, Tissue Distribution, Excretion, and Metabolism of β-Cyclodextrin in Rats Abstract β-cyclodextrin has a unique annular hollow ultrastructure that allows encapsulation of various poorly water-soluble drugs in the resulting cavity, thereby i...
PMC7744986
core_pubmed_pmc
A Phase 1, Placebo-controlled, Randomized, Single Ascending Dose Study and a Volunteer Infection Study to Characterize the Safety, Pharmacokinetics, and Antimalarial Activity of the Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048
A Phase 1, Placebo-controlled, Randomized, Single Ascending Dose Study and a Volunteer Infection Study to Characterize the Safety, Pharmacokinetics, and Antimalarial Activity of the Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048 Abstract Abstract Background MMV390048 is the first Plasmodium phosphatidylin...
PMC11428499
core_pubmed_pmc
Antibacterial and Antibiofilm Potential of Chlorophyllin Against Streptococcus mutans In Vitro and In Silico
Antibacterial and Antibiofilm Potential of Chlorophyllin Against Streptococcus mutans In Vitro and In Silico Abstract Abstract Background: Streptococcus mutans is a leading causative agent of dental caries and exerts pathogenicity by forming biofilms. Dental caries continues to be a significant public health issue worl...
PMC4264453
core_pubmed_pmc
Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors
Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors Abstract Background: Eribulin mesylate is a synthetic macrocyclic ketone analogue of Halichondrin B that has demonstrated high antitumor activity in preclinical and clinical settings. This phase I study...
PMC11469255
core_pubmed_pmc
Polymer‐Based mRNA Delivery Strategies for Advanced Therapies
Polymer‐Based mRNA Delivery Strategies for Advanced Therapies Abstract Abstract Messenger RNA (mRNA)‐based therapies offer great promise for the treatment of a variety of diseases. In 2020, two FDA approvals of mRNA‐based vaccines have elevated mRNA vaccines to global recognition. However, the therapeutic capabilities ...
PMC9147581
core_pubmed_pmc
Pharmacokinetics of the Anti-Inflammatory Drug Meloxicam after Single 1.5 mg/kg Intramuscular Administration to Undulate Skates ( Raja undulata )
Pharmacokinetics of the Anti-Inflammatory Drug Meloxicam after Single 1.5 mg/kg Intramuscular Administration to Undulate Skates ( Raja undulata ) Abstract The therapy database currently used in elasmobranchs is still mostly based on empirical data, and there are few efficacy and safety studies supporting clinical pract...
PMC9405430
core_pubmed_pmc
The pharmacokinetic and pharmacodynamic properties and short-term outcome of a novel once-weekly PEGylated recombinant human growth hormone for children with growth hormone deficiency
The pharmacokinetic and pharmacodynamic properties and short-term outcome of a novel once-weekly PEGylated recombinant human growth hormone for children with growth hormone deficiency Abstract Objectives To investigate the pharmacokinetics (PK) and pharmacodynamics (PD) of Y-shape branched PEGylated recombinant human g...
PMC12954118
core_pubmed_pmc
Integrated virtual screening, ADMET profiling, and molecular dynamics simulations of novel natural HDAC6 inhibitors with the potential to ameliorate skeletal muscle degeneration
Integrated virtual screening, ADMET profiling, and molecular dynamics simulations of novel natural HDAC6 inhibitors with the potential to ameliorate skeletal muscle degeneration Abstract Histone deacetylase 6 (HDAC6) helps maintain muscle health and regulates protein balance. In atrophic muscle, increased HDAC6 activit...
PMC11118786
core_pubmed_pmc
Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review
Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review Abstract Objective To review the pharmacokinetic (PK)–pharmacodynamic (PD) profiles, disease setting, dosing, and safety of oral and par...
PMC11109052
core_pubmed_pmc
Metabolism characterization and toxicity of N -hydap, a marine candidate drug for lung cancer therapy by LC–MS method
Metabolism characterization and toxicity of N -hydap, a marine candidate drug for lung cancer therapy by LC–MS method Abstract Abstract N -Hydroxyapiosporamide ( N -hydap), a marine product derived from a sponge-associated fungus, has shown promising inhibitory effects on small cell lung cancer (SCLC). However, there i...
PMC10966820
core_pubmed_pmc
Precise infliximab exposure and pharmacodynamic control to achieve deep remission in paediatric Crohn’s disease (REMODEL-CD): study protocol for a multicentre, open-label, pragmatic clinical trial in the USA
Precise infliximab exposure and pharmacodynamic control to achieve deep remission in paediatric Crohn’s disease (REMODEL-CD): study protocol for a multicentre, open-label, pragmatic clinical trial in the USA Abstract Introduction The only biologic therapy currently approved to treat moderate to severe Crohn’s disease i...
PMC4269305
core_pubmed_pmc
The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid
The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid Abstract Abstract In the development of central nervous system (CNS)-targeted drugs, the prediction of human CNS target exposure is a big challenge. Cerebrospinal fluid (CSF) concentrations have often been sugge...
PMC12300145
core_pubmed_pmc
Syzygium aromaticum Phytoconstituents Target SARS-CoV-2: Integrating Molecular Docking, Dynamics, Pharmacokinetics, and miR-21 rs1292037 Genotyping
Syzygium aromaticum Phytoconstituents Target SARS-CoV-2: Integrating Molecular Docking, Dynamics, Pharmacokinetics, and miR-21 rs1292037 Genotyping Abstract Background and aim: The COVID-19 pandemic, caused by SARS-CoV-2, remains a global health crisis despite vaccination efforts, necessitating novel therapeutic strate...
PMC10769161
core_pubmed_pmc
A Randomized Clinical Trial of Bayesian-Guided Beta-Lactam Infusion Strategy and Associated Bacterial Resistance and Clinical Outcomes in Patients With Severe Pneumonia
A Randomized Clinical Trial of Bayesian-Guided Beta-Lactam Infusion Strategy and Associated Bacterial Resistance and Clinical Outcomes in Patients With Severe Pneumonia Abstract Supplemental Digital Content is Available in the Text. Background: Antimicrobial resistance is a growing health concern worldwide. The objecti...
PMC5754411
core_pubmed_pmc
Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14 C-microtracer and therapeutic dose in cancer patients
Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14 C-microtracer and therapeutic dose in cancer patients Abstract Abstract Introduction Niraparib (Zejula™) is a poly(ADP-ribose) polymerase inhibitor recently approved by the US Food and Drug Administration for the main...
PMC11417154
core_pubmed_pmc
Pharmacokinetics and Pharmacodynamics of Inhaled Nicotine Salt and Free-Base Using an E-cigarette: A Randomized Crossover Study
Pharmacokinetics and Pharmacodynamics of Inhaled Nicotine Salt and Free-Base Using an E-cigarette: A Randomized Crossover Study Abstract Abstract Introduction Popular “pod-style” e-cigarettes commonly use nicotine salt-based e-liquids that cause less irritation when inhaled and can deliver higher nicotine concentration...
PMC8332597
core_pubmed_pmc
Effect of Varying Degrees of Renal Impairment on the Pharmacokinetics of Omecamtiv Mecarbil
Effect of Varying Degrees of Renal Impairment on the Pharmacokinetics of Omecamtiv Mecarbil Abstract Background and Objective Omecamtiv mecarbil is a novel selective cardiac myosin activator (myotrope) under investigation for the treatment of heart failure with reduced ejection fraction. The objective of this clinical ...
PMC4887780
core_pubmed_pmc
A pharmacokinetic study of Isatin in Beagles' bodies
A pharmacokinetic study of Isatin in Beagles' bodies Abstract Abstract Isatin are marine active drugs that exert anti-cancer effects, have a cancer-prevention function, and possess many pharmacological activities. The study aimed to examine the pharmacokinetics of a single intravenous injection and oral medication of I...
PMC11299312
core_pubmed_pmc
The elasticity of silicone-stabilized liposomes has no impact on their in vivo behavior
The elasticity of silicone-stabilized liposomes has no impact on their in vivo behavior Abstract Abstract Background The elastomechanical properties of nanocarriers have recently been discussed as important for the efficient delivery of various therapeutics. Some data indicate that optimal nanocarriers’ elasticity can ...
PMC3540360
core_pubmed_pmc
Feasibility, safety and pharmacokinetic study of hepatic administration of drug-eluting beads loaded with irinotecan (DEBIRI) followed by intravenous administration of irinotecan in a porcine model
Feasibility, safety and pharmacokinetic study of hepatic administration of drug-eluting beads loaded with irinotecan (DEBIRI) followed by intravenous administration of irinotecan in a porcine model Abstract Irinotecan eluting embolization beads (DEBIRI) are currently being evaluated in the clinic for the treatment of c...
PMC8359279
core_pubmed_pmc
Population pharmacokinetics of clofarabine for allogeneic hematopoietic cell transplantation in paediatric patients
Population pharmacokinetics of clofarabine for allogeneic hematopoietic cell transplantation in paediatric patients Abstract Aims Clofarabine has recently been evaluated as part of the conditioning regimen for allogeneic hematopoietic stem cell transplantation (HCT) in children. Pharmacokinetic (PK) exposure of differe...
PMC10077575
core_pubmed_pmc
Cost-Effective Pipeline for a Rational Design and Selection of Capsaicin Analogues Targeting TRPV1 Channels
Cost-Effective Pipeline for a Rational Design and Selection of Capsaicin Analogues Targeting TRPV1 Channels Abstract Abstract Transient receptor potential (TRP) channels constitute a large group of membrane receptors associated with sensory pathways in vertebrates. One of the most studied is TRPV1, a polymodal receptor...
PMC10088080
core_pubmed_pmc
Population pharmacokinetics and exposure–clinical outcome relationship of remdesivir major metabolite GS ‐441524 in patients with moderate and severe COVID ‐19
Population pharmacokinetics and exposure–clinical outcome relationship of remdesivir major metabolite GS ‐441524 in patients with moderate and severe COVID ‐19 Abstract Abstract Although remdesivir, a prodrug of nucleoside analog (GS‐441524), has demonstrated clinical benefits in coronavirus disease 2019 (COVID‐19) tre...
PMC5301048
core_pubmed_pmc
Selection and early clinical evaluation of the brain‐penetrant 11β‐hydroxysteroid dehydrogenase type 1 (11β‐HSD1) inhibitor UE2343 (Xanamem™)
Selection and early clinical evaluation of the brain‐penetrant 11β‐hydroxysteroid dehydrogenase type 1 (11β‐HSD1) inhibitor UE2343 (Xanamem™) Abstract Abstract Background and Purpose Reducing glucocorticoid exposure in the brain via intracellular inhibition of the cortisol‐regenerating enzyme 11β‐hydroxysteroid dehydro...
PMC8194226
core_pubmed_pmc
Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup
Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup Abstract Background β-adrenergic antagonists (BAAs) are used to treat cardiovascular disease such as ischemic heart disease, congestive heart failure, dysrhythmias, and hypertension. Po...
PMC6226823
core_pubmed_pmc
Pharmacokinetic data of synthetic cathinones in female Sprague-Dawley rats
Pharmacokinetic data of synthetic cathinones in female Sprague-Dawley rats Abstract Abstract The synthetic cathinones methylone, butylone, and pentylone differ from each other through the one carbon lengthening of the α-alkyl chain: methylone (-CH3), butylone (-CH2CH3), and pentylone (-CH2CH2CH3) while 3,4-methylenedio...
PMC12283251
core_pubmed_pmc
Sustained HIV Viral Suppression 18 Months After the Last Dose of Long-acting Cabotegravir/Rilpivirine: A Case Report
Sustained HIV Viral Suppression 18 Months After the Last Dose of Long-acting Cabotegravir/Rilpivirine: A Case Report Abstract Abstract Long-acting cabotegravir/rilpivirine offers a low incidence of virologic failure. However, drug resistance can develop after discontinuation without an effective replacement regimen due...
PMC9453112
core_pubmed_pmc
A Rational Approach to Drug Repositioning in β-thalassemia: Induction of Fetal Hemoglobin by Established Drugs
A Rational Approach to Drug Repositioning in β-thalassemia: Induction of Fetal Hemoglobin by Established Drugs Abstract Abstract Drug repositioning and the relevance of orphan drug designation for β-thalassemia is reviewed. Drug repositioning and similar terms ('drug repurposing', 'drug reprofiling', 'drug redirecting'...
PMC8957881
core_pubmed_pmc
Ex Vivo Pharmacokinetics and Pharmacodynamics Modeling and Optimal Regimens Evaluation of Cefquinome Against Bovine Mastitis Caused by Staphylococcus aureus
Ex Vivo Pharmacokinetics and Pharmacodynamics Modeling and Optimal Regimens Evaluation of Cefquinome Against Bovine Mastitis Caused by Staphylococcus aureus Abstract Cefquinome, the fourth-generation cephalosporin applied solely for veterinary medicine, is commonly used for bovine mastitis caused by Staphylococcus aure...
PMC10832586
core_pubmed_pmc
Synergy of polymyxin B and minocycline against KPC-3- and OXA-48-producing Klebsiella pneumoniae in dynamic time–kill experiments: agreement with in silico predictions
Synergy of polymyxin B and minocycline against KPC-3- and OXA-48-producing Klebsiella pneumoniae in dynamic time–kill experiments: agreement with in silico predictions Abstract Abstract Objectives Combination therapy is often used for carbapenem-resistant Gram-negative bacteria. We previously demonstrated synergy of po...
PMC5744175
core_pubmed_pmc
Pharmacokinetics and Pharmacodynamics of Meloxicam in East Asian Populations: The Role of Ethnicity on Drug Response
Pharmacokinetics and Pharmacodynamics of Meloxicam in East Asian Populations: The Role of Ethnicity on Drug Response Abstract Abstract We aimed to reanalyze the differences in the pharmacokinetics (PKs) of meloxicam in East Asian populations based on a population approach using previously published data and to investig...
PMC12167919
core_pubmed_pmc
Precision Medicine in Oncology: Imatinib Dosing in the Obese Cancer Population Using Virtual Clinical Trials
Precision Medicine in Oncology: Imatinib Dosing in the Obese Cancer Population Using Virtual Clinical Trials Abstract ABSTRACT This study investigates the impact of obesity on imatinib pharmacokinetics in cancer patients by utilizing physiologically based pharmacokinetic modeling (PBPK) and virtual clinical trial appro...
PMC10011276
core_pubmed_pmc
[ 18 F]Fluoride uptake in various bone types and soft tissues in rat
[ 18 F]Fluoride uptake in various bone types and soft tissues in rat Abstract Abstract Background In the development of new 18 F-labelled tracers, it is important to assess the amount of released [ 18 F]fluoride taken up in the bones of experimental animals because all 18 F-labelled PET-tracers are prone, to lesser or ...
PMC11024034
core_pubmed_pmc
Pharmacokinetic Profile of Brepocitinib with Topical Administration in Atopic Dermatitis and Psoriasis Populations: Strategy to Inform Clinical Trial Design in Adult and Pediatric Populations
Pharmacokinetic Profile of Brepocitinib with Topical Administration in Atopic Dermatitis and Psoriasis Populations: Strategy to Inform Clinical Trial Design in Adult and Pediatric Populations Abstract Introduction Topical brepocitinib, a tyrosine kinase (TYK)2/Janus kinase (JAK)1 inhibitor, is in development for psoria...
PMC8434762
core_pubmed_pmc
Phenytoin Pharmacokinetics During Venoarterial Extracorporeal Membrane Oxygenation and Plasma Exchange
Phenytoin Pharmacokinetics During Venoarterial Extracorporeal Membrane Oxygenation and Plasma Exchange Abstract Abstract Currently, there is minimal guidance to antiepileptic dose adjustment for a patient requiring either venoarterial (VA) extracorporeal membrane oxygenation (ECMO) or plasma exchange (PLEX) therapy, an...
PMC10980839
core_pubmed_pmc
The Impact of Baohuoside I on the Metabolism of Tofacitinib in Rats
The Impact of Baohuoside I on the Metabolism of Tofacitinib in Rats Abstract Abstract Purpose To study the potential drug–drug interactions between tofacitinib and baohuoside I and to provide the scientific basis for rational use of them in clinical practice. Methods A total of eighteen Sprague-Dawley rats were randoml...
PMC7909806
core_pubmed_pmc
Model-Based Prediction to Evaluate Residence Time of Hyaluronic Acid Based Dermal Fillers
Model-Based Prediction to Evaluate Residence Time of Hyaluronic Acid Based Dermal Fillers Abstract Dermal fillers are gel-type substances for nonsurgical medical-device use to achieve facial rejuvenation. Currently, the most widely used skin fillers are hyaluronic-acid-based dermal fillers. This study aimed to explain ...
PMC9294860
core_pubmed_pmc
Non‐clinical considerations for supporting accelerated inclusion of pregnant women in pre‐licensure clinical trials with anti‐HIV agents
Non‐clinical considerations for supporting accelerated inclusion of pregnant women in pre‐licensure clinical trials with anti‐HIV agents Abstract Abstract Introduction To allow the continued participation of women enrolled in pre‐licensure clinical trials who become pregnant, and to potentially enrol pregnant women in ...
PMC12340732
core_pubmed_pmc
A Large Cohort Study to Identify Risk Factors of Acute Kidney Injury in Pediatric Patients Undergoing Intravenous Vancomycin Therapy
A Large Cohort Study to Identify Risk Factors of Acute Kidney Injury in Pediatric Patients Undergoing Intravenous Vancomycin Therapy Abstract ABSTRACT Background and Objectives The relative contribution of vancomycin exposure versus clinical factors to acute kidney injury (AKI) development in pediatric patients remains...
PMC8397403
core_pubmed_pmc
Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Disposition of Imaging Biomarker Gadoxetate in Rats
Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Disposition of Imaging Biomarker Gadoxetate in Rats Abstract Abstract Physiologically based pharmacokinetic (PBPK) models are increasingly used in drug development to simulate changes in both systemic and tissue exposures that arise as a res...
PMC8661500
core_pubmed_pmc
Interactions Between Ephedra sinica and Prunus armeniaca : From Stereoselectivity to Deamination as a Metabolic Detoxification Mechanism of Amygdalin
Interactions Between Ephedra sinica and Prunus armeniaca : From Stereoselectivity to Deamination as a Metabolic Detoxification Mechanism of Amygdalin Abstract Mahuang–Xingren (MX, Ephedra sinica Stapf- Prunus armeniaca L.) is a classic herb pair used in traditional Chinese medicine. This combined preparation reduces th...
PMC12891893
core_pubmed_pmc
Rapid in vivo release of paclitaxel from polymeric micelles
Rapid in vivo release of paclitaxel from polymeric micelles Abstract Profiling in vivo release kinetics of drug nanocarriers is of high translational significance. However, this has remained unrealized due to the lack of direct methodologies to quantify either the total released or residual drugs. This study employed a...
PMC7520419
core_pubmed_pmc
Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective
Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective Abstract The effect of food on pharmacokinetic properties of drugs is a commonly observed occurrence affecting about 40% of orally administered drugs. Within the pharmaceutical industry, significa...
PMC4471785
core_pubmed_pmc
Aspartate-modified doxorubicin on its N -terminal increases drug accumulation in LAT1 -overexpressing tumors
Aspartate-modified doxorubicin on its N -terminal increases drug accumulation in LAT1 -overexpressing tumors Abstract Abstract L-type amino acid transporter 1 (LAT1), overexpressed on the membrane of various tumor cells, is a potential target for tumor-targeting therapy. This study aimed to develop a LAT1 -mediated che...
PMC10569024
core_pubmed_pmc
Pharmacokinetic–pharmacodynamic analysis of cefmetazole against extended-spectrum β-lactamase-producing Enterobacteriaceae in dogs using Monte Carlo Simulation
Pharmacokinetic–pharmacodynamic analysis of cefmetazole against extended-spectrum β-lactamase-producing Enterobacteriaceae in dogs using Monte Carlo Simulation Abstract Abstract Introduction The spread of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) is a serious concern in companion animal medici...
PMC11739739
core_pubmed_pmc
An IQ Industry Perspective on Informing Dosing Recommendations in Patients With Renal Impairment
An IQ Industry Perspective on Informing Dosing Recommendations in Patients With Renal Impairment Abstract Abstract The IQ CPLG Organ Impairment WG conducted a survey to understand how various IQ member companies develop dosing recommendations for patients with renal impairment. Eighteen IQ member companies participated...
PMC7830424
core_pubmed_pmc
Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives
Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives Abstract Treatment options for retinal diseases, such as neovascular age-related macular degeneration, diabetic retinopathy, and retinal vascular disorders, have markedly expanded following the development of anti-vascular endothelial growt...
PMC8007387
core_pubmed_pmc
Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor
Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor Abstract Abstract Remdesivir (RDV, Veklury ® ) is a once-daily, nucleoside ribonucleic acid polymerase inhibitor of severe acute respiratory syndrome coronavirus 2 replication. Remdesivir has been granted ap...
PMC4068537
core_pubmed_pmc
Benefits of a Pharmacology Antimalarial Reference Standard and Proficiency Testing Program Provided by the Worldwide Antimalarial Resistance Network (WWARN)
Benefits of a Pharmacology Antimalarial Reference Standard and Proficiency Testing Program Provided by the Worldwide Antimalarial Resistance Network (WWARN) Abstract Abstract Comprehensive assessment of antimalarial drug resistance should include measurements of antimalarial blood or plasma concentrations in clinical t...
PMC10885322
core_pubmed_pmc
Enhancing Quantitative Analysis of Xenobiotics in Blood Plasma through Cross-Matrix Calibration and Bayesian Hierarchical Modeling
Enhancing Quantitative Analysis of Xenobiotics in Blood Plasma through Cross-Matrix Calibration and Bayesian Hierarchical Modeling Abstract This study addresses the challenges of matrix effects and interspecies plasma protein binding (PPB) on measurement variability during method validation across diverse plasma types ...
PMC9617509
core_pubmed_pmc
Evaluation of Molecular Properties versus In Vivo Performance of Aflibercept, Brolucizumab, and Ranibizumab in a Retinal Vascular Hyperpermeability Model
Evaluation of Molecular Properties versus In Vivo Performance of Aflibercept, Brolucizumab, and Ranibizumab in a Retinal Vascular Hyperpermeability Model Abstract Abstract Purpose To evaluate the molecular, pharmacokinetic, and pharmacological properties of three anti-vascular endothelial growth factor (VEGF) agents—af...
PMC3870994
core_pubmed_pmc
Phase I drug-interaction study of effects of calcium and magnesium infusions on oxaliplatin pharmacokinetics and acute neurotoxicity in colorectal cancer patients
Phase I drug-interaction study of effects of calcium and magnesium infusions on oxaliplatin pharmacokinetics and acute neurotoxicity in colorectal cancer patients Abstract Background Calcium and magnesium (Ca/Mg) infusions have been suggested as an effective intervention for preventing oxaliplatin-induced neurotoxicity...
PMC7898221
core_pubmed_pmc
Pharmacokinetic and Pharmacodynamic Comparison of Two Formulations of a Fixed-Dose Combination of Gemigliptin/Rosuvastatin 50/20 mg: A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study
Pharmacokinetic and Pharmacodynamic Comparison of Two Formulations of a Fixed-Dose Combination of Gemigliptin/Rosuvastatin 50/20 mg: A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study Abstract Abstract Purpose A fixed-dose combination (FDC) of gemigliptin/rosuvastatin 50/20 mg as a monolayer tablet has been...
PMC11003274
core_pubmed_pmc
Pharmacokinetics and pharmacodynamics of mibavademab (a leptin receptor agonist): Results from a first‐in‐human phase I study
Pharmacokinetics and pharmacodynamics of mibavademab (a leptin receptor agonist): Results from a first‐in‐human phase I study Abstract Abstract Mibavademab (previously known as REGN4461), a fully human monoclonal antibody, is being investigated for the treatment of conditions associated with leptin deficiency. Here, we...
PMC12653751
core_pubmed_pmc
Therapeutic Drug Monitoring in Special Circumstances in Inflammatory Bowel Disease
Therapeutic Drug Monitoring in Special Circumstances in Inflammatory Bowel Disease Abstract Abstract Inflammatory bowel disease, encompassing ulcerative colitis and Crohn’s disease, is characterised by chronic immune-mediated inflammation and variable treatment response. Loss of drug efficacy due to underexposure, phar...
PMC11677509
core_pubmed_pmc
Exploring the Feasibility of a Bracketing Approach Utilizing Modeling for Development of Long-Acting Injectables for Regulatory Approval—A Case Study Using Levonorgestrel
Exploring the Feasibility of a Bracketing Approach Utilizing Modeling for Development of Long-Acting Injectables for Regulatory Approval—A Case Study Using Levonorgestrel Abstract Abstract Background: The development of long-acting products of a characterized drug substance is of great interest. It is possible to suppo...
PMC12862872
core_pubmed_pmc
TMPRSS2 inhibitors with broad-spectrum efficacy against SARS-CoV-2 (JN.1) and influenza A (H1N1) viruses protect mice from influenza A infection
TMPRSS2 inhibitors with broad-spectrum efficacy against SARS-CoV-2 (JN.1) and influenza A (H1N1) viruses protect mice from influenza A infection Abstract ABSTRACT Human TMPRSS2 is a type II transmembrane serine protease and an essential host factor for SARS-CoV-2 and influenza A virus (IAV H1N1) infections. It facilita...
PMC7846863
core_pubmed_pmc
Response Surface Optimization of Ultra-Elastic Nanovesicles Loaded with Deflazacort Tailored for Transdermal Delivery: Accentuated Bioavailability and Anti-Inflammatory Efficacy
Response Surface Optimization of Ultra-Elastic Nanovesicles Loaded with Deflazacort Tailored for Transdermal Delivery: Accentuated Bioavailability and Anti-Inflammatory Efficacy Abstract Purpose The aim of the present study was to develop deflazacort (DFZ) ultra-elastic nanovesicles (UENVs) loaded gel for topical admin...
PMC11413788
core_pubmed_pmc
The heterobivalent (SSTR2/albumin) radioligand [ 67 Cu]Cu-NODAGA-cLAB4-TATE enables efficient somatostatin receptor radionuclide theranostics
The heterobivalent (SSTR2/albumin) radioligand [ 67 Cu]Cu-NODAGA-cLAB4-TATE enables efficient somatostatin receptor radionuclide theranostics Abstract Abstract Somatostatin type 2 receptor (SSTR2) radionuclide therapy using β - particle-emitting radioligands has entered clinical practice for the treatment of neuroendoc...
PMC8270635
core_pubmed_pmc
The enhanced bioavailability of free curcumin and bioactive-metabolite tetrahydrocurcumin from a dispersible, oleoresin-based turmeric formulation
The enhanced bioavailability of free curcumin and bioactive-metabolite tetrahydrocurcumin from a dispersible, oleoresin-based turmeric formulation Abstract Abstract Background: Curcuminoids have been widely studied for human health and disease applications, yet bioavailability remains a hurdle to actualizing all the be...
PMC12072230
core_pubmed_pmc
A Population Pharmacokinetic Model to Inform Extension of the Eteplirsen Dosing Regimen Across the Broad DMD Population
A Population Pharmacokinetic Model to Inform Extension of the Eteplirsen Dosing Regimen Across the Broad DMD Population Abstract ABSTRACT Duchenne muscular dystrophy (DMD) is characterized by progressive, irreversible muscle damage that usually leads to premature death from cardiac or respiratory failure. Eteplirsen is...
PMC4971586
core_pubmed_pmc
Pharmacokinetics and Metabolism of Cyadox and Its Main Metabolites in Beagle Dogs Following Oral, Intramuscular, and Intravenous Administration
Pharmacokinetics and Metabolism of Cyadox and Its Main Metabolites in Beagle Dogs Following Oral, Intramuscular, and Intravenous Administration Abstract Cyadox (Cyx) is an antibacterial drug of the quinoxaline group that exerts markedly lower toxicity in animals, compared to its congeners. Here, the pharmacokinetics an...
PMC10007630
core_pubmed_pmc
Evolution of Portable Sensors for In-Vivo Dose and Time-Activity Curve Monitoring as Tools for Personalized Dosimetry in Molecular Radiotherapy
Evolution of Portable Sensors for In-Vivo Dose and Time-Activity Curve Monitoring as Tools for Personalized Dosimetry in Molecular Radiotherapy Abstract Treatment personalization in Molecular Radiotherapy (MRT) relies on pre- and post-treatment SPECT/ PET-based images and measurements to obtain a patient-specific absor...
PMC5447713
core_pubmed_pmc
The PK–PD Relationship and Resistance Development of Danofloxacin against Mycoplasma gallisepticum in An In Vivo Infection Model
The PK–PD Relationship and Resistance Development of Danofloxacin against Mycoplasma gallisepticum in An In Vivo Infection Model Abstract Abstract Mycoplasma gallisepticum is the causative agent of chronic respiratory disease (CRD), a prevalent disease of poultry, which is responsible for significant economic losses in...
PMC5193075
core_pubmed_pmc
Quantitative Assessment of Population Variability in Hepatic Drug Metabolism Using a Perfused Three-Dimensional Human Liver Microphysiological System
Quantitative Assessment of Population Variability in Hepatic Drug Metabolism Using a Perfused Three-Dimensional Human Liver Microphysiological System Abstract Abstract In this work, we first describe the population variability in hepatic drug metabolism using cryopreserved hepatocytes from five different donors culture...
PMC9540489
core_pubmed_pmc
Exposure of Fexofenadine, but Not Pseudoephedrine, Is Markedly Decreased by Green Tea Extract in Healthy Volunteers
Exposure of Fexofenadine, but Not Pseudoephedrine, Is Markedly Decreased by Green Tea Extract in Healthy Volunteers Abstract Abstract Green tea (GT) alters the disposition of a number of drugs, such as nadolol and lisinopril. However, it is unknown whether GT affects disposition of hydrophilic anti‐allergic drugs. The ...
PMC11336434
core_pubmed_pmc
Anti-angiogenic activity of a novel angiostatin-like plasminogen fragment produced by a bacterial metalloproteinase
Anti-angiogenic activity of a novel angiostatin-like plasminogen fragment produced by a bacterial metalloproteinase Abstract Abstract Tumor growth depends on angiogenesis, a process by which new blood vessel are formed from pre-existing normal blood vessels. Proteolytic fragments of plasminogen, containing varying numb...
PMC10154516
core_pubmed_pmc
Potential profound fluctuation in tacrolimus concentration on consumption of pomegranate rind extract: A Pharmacokinetic Experiment
Potential profound fluctuation in tacrolimus concentration on consumption of pomegranate rind extract: A Pharmacokinetic Experiment Abstract Abstract Background: Presently, varied case reports demonstrated an increase or decrease in blood concentration of diverse conventional drugs, often co-administered with edible fr...
PMC9541356
core_pubmed_pmc
Short‐ and long‐term effects of body weight, calorie restriction and gastric bypass on CYP1A2, CYP2C19 and CYP2C9 activity
Short‐ and long‐term effects of body weight, calorie restriction and gastric bypass on CYP1A2, CYP2C19 and CYP2C9 activity Abstract Abstract Aim Roux‐en‐Y gastric bypass (RYGB) may influence drug disposition due to surgery‐induced gastrointestinal alterations and/or subsequent weight loss. The objective was to compare ...
PMC7528021
core_pubmed_pmc
Influence of Different Dosage Forms on Pharmacokinetics of 6 Alkaloids in Raw Aconiti Kusnezoffii Radix ( Caowu ) and Chebulae Fructus- ( Hezi -) Processed Caowu by UPLC-MS/MS
Influence of Different Dosage Forms on Pharmacokinetics of 6 Alkaloids in Raw Aconiti Kusnezoffii Radix ( Caowu ) and Chebulae Fructus- ( Hezi -) Processed Caowu by UPLC-MS/MS Abstract Purpose To study the pharmacokinetics of the 6 alkaloids (aconitine, mesaconitine, hypaconitine, benzoylaconine, benzoylmesaconine, and...
PMC11078288
core_pubmed_pmc
Effect of Metformin on Plasma Exposure of Rifampicin, Isoniazid, and Pyrazinamide in Patients on Treatment for Pulmonary Tuberculosis
Effect of Metformin on Plasma Exposure of Rifampicin, Isoniazid, and Pyrazinamide in Patients on Treatment for Pulmonary Tuberculosis Abstract Background: To evaluate the effect of metformin on the plasma levels of rifampicin, isoniazid, and pyrazinamide in patients with drug-sensitive pulmonary tuberculosis being trea...
PMC10508530
core_pubmed_pmc
Model‐based prediction of progression‐free survival for combination therapies in oncology
Model‐based prediction of progression‐free survival for combination therapies in oncology Abstract Abstract Progression‐free survival (PFS) is an important clinical metric for comparing and evaluating similar treatments for the same disease within oncology. After the completion of a clinical trial, a descriptive analys...
PMC10526844
core_pubmed_pmc
Resveratrol-Laden Nano-Systems in the Cancer Environment: Views and Reviews
Resveratrol-Laden Nano-Systems in the Cancer Environment: Views and Reviews Abstract Abstract Simple Summary Resveratrol, a polyphenolic stilbene derivative, is gaining popularity in cancer treatment for its antioxidant and anti-inflammatory properties. However, its pharmacokinetic and physicochemical limitations, such...
PMC8217058
core_pubmed_pmc
A Liposomal Gemcitabine, FF-10832, Improves Plasma Stability, Tumor Targeting, and Antitumor Efficacy of Gemcitabine in Pancreatic Cancer Xenograft Models
A Liposomal Gemcitabine, FF-10832, Improves Plasma Stability, Tumor Targeting, and Antitumor Efficacy of Gemcitabine in Pancreatic Cancer Xenograft Models Abstract Abstract Purpose The clinical application of gemcitabine (GEM) is limited by its pharmacokinetic properties. The aim of this study was to characterize the s...
PMC3546104
core_pubmed_pmc
Serum Cystatin C Is a Major Predictor of Vancomycin Clearance in a Population Pharmacokinetic Analysis of Patients with Normal Serum Creatinine Concentrations
Serum Cystatin C Is a Major Predictor of Vancomycin Clearance in a Population Pharmacokinetic Analysis of Patients with Normal Serum Creatinine Concentrations Abstract We developed a population pharmacokinetic model of vancomycin by integrating the effects of cystatin C and other demographic factors in a large populati...